Axonics, Inc.
Clinical trials sponsored by Axonics, Inc., explained in plain language.
Medical device company focused on sacral neuromodulation for bladder and bowel disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New device trial offers hope for bladder and bowel leakage Results expected Nov 2026 (estimated)
- No more charging: new implant aims to ease bladder and bowel leaks Results expected Dec 2026 (estimated)
- Rechargeable implant offers hope for bladder control – but does it last? Results expected Jan 2027 (estimated)
- New implant aims to control bowel leakage Results expected Aug 2027 (estimated)
-
Implant zaps bladder nerves to stop sudden leaks
Disease control CompletedThis study tested a device that uses mild electrical pulses to calm the nerves controlling the bladder. It was for people with sudden, strong urges to urinate that cause leaks, who didn't get help from other treatments. The goal was to see if the device safely reduces leaks by at…
Sponsor: Axonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Nerve zap device shows promise for bladder and bowel woes
Disease control CompletedThis completed study looked at how well the Axonics sacral neuromodulation system works for people with bladder or bowel control problems. 272 participants were tracked to see if their symptoms improved and if the device was safe. The device uses mild electrical pulses to calm ov…
Sponsor: Axonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC